<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511901</url>
  </required_header>
  <id_info>
    <org_study_id>0220045106</org_study_id>
    <nct_id>NCT00511901</nct_id>
  </id_info>
  <brief_title>Prevalence and Treatment of Anemia in Rehabilitation Patients</brief_title>
  <official_title>Prevalence and Treatment of Anemia in Patients Admitted to Subacute Rehabilitation Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech Clinical Affairs, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who are admitted to subacute rehabilitation facilities following hospitalization are
      frequently anemic. The purpose of this study is to see if anemic patients treated with
      epoetin alfa will have higher hemoglobin levels and better functional recovery at 3, 8, and
      12 weeks after study entry compared to patients who do not receive epoetin alfa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia is associated with loss of function in some studies. However, it is unknown if more
      rapid correction of anemia in patients who enter a rehabilitation setting after surgery or
      from hospitalization for acute medical problems leads to shorter rehabilitation stays and
      improved functional status.

      Patients aged 60 and older who have hemoglobin levels of less than 10.5 g/dL will be
      randomized to receive 8 weekly doses of either erythropoietin alfa or placebo. Functional
      status will be measured at baseline and then at 3, 8 and 12 weeks.

      The following specific aims will be tested in this study:

        -  Determine the prevalence of anemia in patients admitted to a subacute rehabilitation
           facility with potential for recovery.

        -  Determine the baseline functional status of patients admitted to a subacute
           rehabilitation facility with potential for recovery using the Functional Independence
           Measure (FIM), an assessment tool used in acute rehabilitation settings.

        -  Determine if administration of epoetin alfa will result in higher hemoglobin
           concentrations in patients receiving the drug than in patients given placebo at 3, 8 and
           12 weeks after entry into the study.

        -  Perform a study that establishes the feasibility of a trial to test whether epoetin alfa
           produces improvements in the FIM, grip strength, the time it takes for patients to reach
           rehabilitation goals, activity monitor, fatigue, mood, functional recovery and reduces
           length of rehabilitation stay.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study enrollment was suspended in response to an FDA alert regarding the study drug. The study
    was subsequently terminated
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Hemoglobin Concentration at 8 Weeks After Entry Into the Study</measure>
    <time_frame>8 weeks following randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor-FIM Score</measure>
    <time_frame>3, 8, and 12 weeks following randomization</time_frame>
    <description>FIM Motor score ranges from 13 to 91 (most independent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in Subacute Rehabilitation Facility</measure>
    <time_frame>12 weeks following randomization</time_frame>
    <description>Days from randomization to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>3, 8, and 12 weeks following randomization</time_frame>
    <description>kilograms measured by hand held dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Physical Performance Battery (SPPB) Score</measure>
    <time_frame>3, 8, and 12 weeks following randomization</time_frame>
    <description>Measure physical function scored 0 - 12 (better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACIT Measurement System Fatigue Scale</measure>
    <time_frame>3, 8, and 12 weeks following randomization</time_frame>
    <description>Fatigue score ranges from 0 to 72. Lower score represents less fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity Counts</measure>
    <time_frame>3, 8, and 12 weeks following randomization</time_frame>
    <description>Activity counts as measured by the Actigraph monitor. Higher counts indicate more activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POMS Depression-Dejection Scale</measure>
    <time_frame>3,8,12 weeks</time_frame>
    <description>Profile of Mood States (POMS) Depression-Dejection Scale 15 item questionnaire to measure the degree of depressive thoughts. The scale ranges from 0 to 60 (most depressed).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Placebo &amp; Niferex</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epoetin alpha &amp; Niferex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo &amp; Niferex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin alpha</intervention_name>
    <arm_group_label>epoetin alpha &amp; Niferex</arm_group_label>
    <other_name>Procrit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niferex</intervention_name>
    <arm_group_label>Placebo &amp; Niferex</arm_group_label>
    <arm_group_label>epoetin alpha &amp; Niferex</arm_group_label>
    <other_name>iron polysaccharide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60 years of age or older

          -  Admission hemoglobin concentration of &lt; 10.5 g/dL.

          -  Able to read and understand English.

          -  Consent signed by subjects.

        Exclusion Criteria:

          -  Unable to randomize within 7 days of admission to rehabilitation center.

          -  Folstein min-mental status score of &lt; 21.

          -  Neuromuscular disease and/or disability; in clinical judgment of the investigators
             that do not have rehabilitation potential.

          -  Diagnosis or evidence of carcinoma (excluding skin cancer other than melanoma) within
             the past five years

          -  Admission for stroke with residual deficit

          -  Wheelchair bound prior to acute event.

          -  Dialysis dependent chronic renal failure

          -  Home more than 1 hour drive from hospital.

          -  Admitted to long term nursing or hospice care.

          -  Active blood loss.

          -  Known history of severe iron deficiency.

          -  Hematological disease that results in anemia that may not respond to erythropoietin
             (including, but not limited to, myelodysplastic syndrome, hematological malignancy,
             hemolytic syndromes, hemoglobinopathy).

          -  Uncontrolled hypertension (systolic BP &gt;200 mmHg or diastolic BP &gt;110 mmHg) after
             adequate antihypertensive therapy.

          -  New onset seizures (within three months) or seizures not controlled by medication.

          -  Objective diagnosis of pulmonary embolism or deep vein thrombosis within the past 10
             years.

          -  Patients with a condition (e.g. psychiatric illness) or in a situation that, in the
             investigator's opinion, may put the subject at significant risk, may confound the
             study results, or may interfere significantly with the subject's compliance with study
             procedures.

          -  Acute burns.

          -  Treatment with any recombinant human erythropoietin within 30 days prior to
             enrollment.

          -  Known hypersensitivity to human albumin or mammalian cell-derived products or
             recombinant human erythropoietin (rHuEPO).

          -  Received an experimental drug or used an experimental medical device within 30 days
             prior to the planned start of treatment.

          -  Pregnancy or lactation.

          -  Employees of the investigator or study center with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Carson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elms of Cranbury</name>
      <address>
        <city>Cranbury</city>
        <state>New Jersey</state>
        <zip>08512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care One East Brunswick</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <results_first_submitted>August 27, 2013</results_first_submitted>
  <results_first_submitted_qc>August 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2013</results_first_posted>
  <last_update_submitted>December 27, 2013</last_update_submitted>
  <last_update_submitted_qc>December 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>function</keyword>
  <keyword>rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Iron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited at two subacute rehabilitation facilities in Central New Jersey between October 2005 and March 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo &amp; Niferex</title>
          <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alpha &amp; Niferex</title>
          <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo &amp; Niferex</title>
          <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alpha &amp; Niferex</title>
          <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.4" spread="8.3"/>
                    <measurement group_id="B2" value="75.5" spread="8.4"/>
                    <measurement group_id="B3" value="75.0" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin Level</title>
          <description>Level Prior to Randomization</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.8" spread="1.0"/>
                    <measurement group_id="B2" value="9.8" spread="0.6"/>
                    <measurement group_id="B3" value="9.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days From Admit to Randomization</title>
          <description># of days from admission to the subacute rehabilitation facility to randomization into the study</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="1.5"/>
                    <measurement group_id="B2" value="5.3" spread="1.8"/>
                    <measurement group_id="B3" value="5.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FIM Motor Scale</title>
          <description>The Functional Independence Measure scale is a 7 point rating scale used as part of the Uniform Data System for Medical Rehabilitation. The FIM motor score ranges from 13 to 91 (most independent).</description>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.2" spread="8.8"/>
                    <measurement group_id="B2" value="68.8" spread="6.9"/>
                    <measurement group_id="B3" value="71.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FACIT Fatigue Scale</title>
          <description>FACIT-Fatigue Scale (version 4) 13 item questionnaire to assess level of fatigue. The FACIT-Fatigue scores range from 0 to 52(most fatigue).</description>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="9.5"/>
                    <measurement group_id="B2" value="29.2" spread="11.6"/>
                    <measurement group_id="B3" value="30.4" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>POMS Depression-Dejection Scale</title>
          <description>Profile of Mood States (POMS) Depression-Dejection Scale 15 item questionnaire to measure the degree of depressive thoughts. The POMS scores range from 0 to 60(most depressed).</description>
          <units>Scores on a Scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="B2" value="3" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="B3" value="3" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Hemoglobin Concentration at 8 Weeks After Entry Into the Study</title>
        <time_frame>8 weeks following randomization</time_frame>
        <population>Intention to treat; of the subjects not lost to follow-up, 3 subjects in the placebo arm &amp; 2 subjects in the epoetin alpha arm were not available for 8 week hemoglobin draw</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Niferex</title>
            <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alpha &amp; Niferex</title>
            <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hemoglobin Concentration at 8 Weeks After Entry Into the Study</title>
          <population>Intention to treat; of the subjects not lost to follow-up, 3 subjects in the placebo arm &amp; 2 subjects in the epoetin alpha arm were not available for 8 week hemoglobin draw</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="1.2"/>
                    <measurement group_id="O2" value="13.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Motor-FIM Score</title>
        <description>FIM Motor score ranges from 13 to 91 (most independent)</description>
        <time_frame>3, 8, and 12 weeks following randomization</time_frame>
        <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Niferex</title>
            <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alpha &amp; Niferex</title>
            <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Motor-FIM Score</title>
          <description>FIM Motor score ranges from 13 to 91 (most independent)</description>
          <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FIM at 3 weeks (n=9; n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="4.4"/>
                    <measurement group_id="O2" value="77.7" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FIM at 8 weeks (n=9; n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="4.2"/>
                    <measurement group_id="O2" value="85.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FIM at 12 weeks (n=10; n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" spread="3.8"/>
                    <measurement group_id="O2" value="85.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FIM at 3 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>.8</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FIM at 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FIM at 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in Subacute Rehabilitation Facility</title>
        <description>Days from randomization to discharge</description>
        <time_frame>12 weeks following randomization</time_frame>
        <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Niferex</title>
            <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alpha &amp; Niferex</title>
            <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in Subacute Rehabilitation Facility</title>
          <description>Days from randomization to discharge</description>
          <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="5.2"/>
                    <measurement group_id="O2" value="17.4" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grip Strength</title>
        <description>kilograms measured by hand held dynamometer</description>
        <time_frame>3, 8, and 12 weeks following randomization</time_frame>
        <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Niferex</title>
            <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alpha &amp; Niferex</title>
            <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Grip Strength</title>
          <description>kilograms measured by hand held dynamometer</description>
          <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grip Strength at 3 weeks (n=9; n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="4.0"/>
                    <measurement group_id="O2" value="18.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grip Strength at 8 weeks (n=9; n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="3.7"/>
                    <measurement group_id="O2" value="19.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grip Strength at 12 weeks (n=10; n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="3.5"/>
                    <measurement group_id="O2" value="19.0" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Grip strength at 3 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Grip strength at 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Grip strength at 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Physical Performance Battery (SPPB) Score</title>
        <description>Measure physical function scored 0 - 12 (better)</description>
        <time_frame>3, 8, and 12 weeks following randomization</time_frame>
        <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Niferex</title>
            <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alpha &amp; Niferex</title>
            <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Short Physical Performance Battery (SPPB) Score</title>
          <description>Measure physical function scored 0 - 12 (better)</description>
          <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPPB at 3 weeks (n=9; n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.9"/>
                    <measurement group_id="O2" value="3.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPPB at 8 weeks (n=9; n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="1.9"/>
                    <measurement group_id="O2" value="7.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPPB at 12 weeks (n=10; n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="2.3"/>
                    <measurement group_id="O2" value="7.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SPPB at 3 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SPPB at 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SPPB at 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FACIT Measurement System Fatigue Scale</title>
        <description>Fatigue score ranges from 0 to 72. Lower score represents less fatigue</description>
        <time_frame>3, 8, and 12 weeks following randomization</time_frame>
        <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Niferex</title>
            <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alpha &amp; Niferex</title>
            <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>FACIT Measurement System Fatigue Scale</title>
          <description>Fatigue score ranges from 0 to 72. Lower score represents less fatigue</description>
          <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FACIT at 3 weeks (n=8; n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="6.7"/>
                    <measurement group_id="O2" value="35.7" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT at 8 weeks (n=9; n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="11.2"/>
                    <measurement group_id="O2" value="42.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT at 12 weeks (n=10; n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="6.7"/>
                    <measurement group_id="O2" value="38.6" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FACIT at 3 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FACIT at 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FACIT at 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activity Counts</title>
        <description>Activity counts as measured by the Actigraph monitor. Higher counts indicate more activity.</description>
        <time_frame>3, 8, and 12 weeks following randomization</time_frame>
        <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Niferex</title>
            <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alpha &amp; Niferex</title>
            <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Activity Counts</title>
          <description>Activity counts as measured by the Actigraph monitor. Higher counts indicate more activity.</description>
          <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
          <units>Counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Activity Counts at 3 weeks (n=8; n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.13" spread="27.0"/>
                    <measurement group_id="O2" value="41.56" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Counts at 8 weeks (n=9; n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.78" spread="32.8"/>
                    <measurement group_id="O2" value="70.17" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Counts at 12 weeks (n=10; n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.60" spread="27.2"/>
                    <measurement group_id="O2" value="77.75" spread="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity Counts at 3 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.57</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity Counts at 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>11.39</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity Counts at 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>16.15</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>POMS Depression-Dejection Scale</title>
        <description>Profile of Mood States (POMS) Depression-Dejection Scale 15 item questionnaire to measure the degree of depressive thoughts. The scale ranges from 0 to 60 (most depressed).</description>
        <time_frame>3,8,12 weeks</time_frame>
        <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Niferex</title>
            <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alpha &amp; Niferex</title>
            <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>POMS Depression-Dejection Scale</title>
          <description>Profile of Mood States (POMS) Depression-Dejection Scale 15 item questionnaire to measure the degree of depressive thoughts. The scale ranges from 0 to 60 (most depressed).</description>
          <population>exact numbers of subjects analyzed at each time point vary based on time of study withdrawal for those who withdrew and availability of subject for those who were under active follow-up</population>
          <units>Scores on a Scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>POMS at 3 weeks (n=9; n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="3.5" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POMS at 8 weeks (n=9; n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POMS at 12 weeks (n=10; n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>POMS at 3 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>POMS at 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>POMS at 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>active followup at 3, 8, &amp; 12 weeks</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo &amp; Niferex</title>
          <description>Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alpha &amp; Niferex</title>
          <description>40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Hip Fracture</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <description>Hip Fracture</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited number of eligible subjects, burdensome protocol requirements impeded recruitment, controversy concerning safety of epoetin alpha which led to early termination of study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey L Carson, MD</name_or_title>
      <organization>University of Medicine and Dentistry of New Jersey</organization>
      <phone>732-235-7122</phone>
      <email>carson@umdnj.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

